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Advancing Novel Science in Women’s Health
Research (ANSWHR) [R21]
The Office of Research on Women’s Health
(ORWH), established in 1990 within the Ofﬁce of
the Director, National Institutes of Health (NIH),
a) advises the NIH Director and staff on matters
relating to research on women’s health; b) strength-
ens and enhances research related to diseases, disor-
ders, and conditions that affect women; c) ensures
that research conducted and supported by NIH
adequately addresses issues regarding women’s
health; d) ensures that women are appropriately
represented in biomedical and biobehavioral
research studies supported by NIH; e) develops
opportunities for and supports recruitment, reten-
tion, reentry, and advancement of women in bio-
medical careers; and f ) supports research on
women’s health issues. ORWH works in partner-
ship with the NIH institutes and centers to ensure
that women’s health research is part of the scientiﬁc
framework at NIH and throughout the scientific
community.
The ORWH announces the publication of an
investigator-initiated exploratory developmental
program, using the R21 grant mechanism. This
trans-NIH research program funding opportunity is
called Advancing Novel Science in Women’s Health
Research (ANSWHR). Using the R21 grant mecha-
nism, ORWH will fund meritorious women’s
health research and sex/gender research in scientiﬁc
partnership with the NIH institutes and centers.
The overall purpose of ANSWHR is to stim-
ulate and support innovative research that will
advance new concepts in women’s health research
and the study of sex/gender differences. ORWH
and its scientiﬁc partners across the NIH are inter-
ested particularly in encouraging extramural inves-
tigators to undertake new interdisciplinary
research to advance studies on how sex and gender
factors affect women’s health.
During the past several years, research reports
have clearly established the importance of studying
issues specific to women and female–male differ-
ences in all areas of science from basic science
studies of molecular genetics to studies of epi-
demiology, etiology, and prevention/treatment
interventions. The scientific and clinical impor-
tance of analyzing data separately for females and
males is becoming more and more evident.
Because ORWH is an ofﬁce within the Ofﬁce
of the NIH Director and does not have “grant-
making authority,” the partnership between
ORWH and the NIH institutes and centers will
be operationalized as follows:
Applications submitted to this Program
Announcement Set-Aside (PAS) will be directed to
the most appropriate NIH institute or center (called
primary IC), based on scientiﬁc focus, by the Center
for Scientiﬁc Review (CSR). Applications will then
undergo standard NIH scientiﬁc review, using estab-
lished Integrated Review Groups (IRG). After scien-
tific review and institute/center council review/
approval, ORWH will provide funding for those
grants selected for award. All pre-award require-
ments and the grant award notice will be handled by
the primary IC. Scientiﬁc and grants management
oversight will reside in the primary NIH institute or
center for the duration of funding, with ORWH
remaining actively involved in this PAS .
The scientific basis for the ANSWHR pro-
gram derives from three main sources: 1) The NIH
Research Priorities for Women’s Health which are
reviewed and published annually on the ORWH
website and is available at:  http://orwh.od.nih.gov/
research/priorities.html; 2) The report, Agenda for
Research on Women’s Health for the 21st Century,
which was developed in collaboration with the NIH
and the extramural scientific and public advocacy
communities; and 3) The Institute of Medicine
Report, “Exploring the Biological Contributions to
Human Health, Does Sex Matter?” Detailed discus-
sion of these sources follows.
FY 2007 NIH Research Priorities for Women’s
Health.  Each year, the ad hoc Research
Subcommittee of the Coordinating Committee on
Research on Women’s Health (CCRWH), com-
posed of representatives from the NIH institutes
and centers, considers continuing gaps in knowl-
edge, and emerging scientiﬁc opportunities for cur-
rent research priorities in women’s health. The
subcommittee’s recommendations are reviewed and
approved by the CCRWH and the Advisory
Committee on Research on Women’s Health
(ACRWH), and posted on the ORWH website,
and is available at: http://orwh.od.nih.gov/research/
priorities.html.
The FY 2007 NIH Research Priorities for
Women’s Health are described in terms of overar-
ching themes, areas of research interest, and spe-
cial emphasis areas. The priorities signify
approaches and areas for which there is a need to
stimulate and encourage research on women’s
health, or sex/gender factors, and the advancement
of women in biomedical research careers. These
research priorities are not an exclusive list of
research areas important to women’s health; there-
fore, other innovative or signiﬁcant research areas
also should be considered.
The following four overarching themes are
important for addressing research on women’s
health: life span, sex/gender determinants, health
disparities/differences and diversity, and inter-
disciplinary research.
Life span. The health of girls and women is
affected by developmental, physiological, and psy-
chological age. Women’s lives are marked by a
continuum from intrauterine life to the elderly
years: infancy, childhood and adolescence, menar-
che, reproductive life, the menopausal transition,
postmenopausal years, the elderly, and the frail
elderly. The lives and health status of women are
influenced by many factors such as work inside
and outside the home; care giving, especially to
children and elder care responsibilities; reproduc-
tive status; marital status; and chronic illness. Each
of these factors may influence health, disease,
lifestyle, treatment choices, and response to ther-
apy. Researchers should consider these variables in
designing studies related to women’s health. 
Sex/gender determinants. Women are charac-
terized by both sex and gender as highlighted in the
Agenda for Research in Women’s Health for the
21st Century and the Institute of Medicine report,
entitled Exploring the Biological Contributions to
Human Health: Does Sex Matter? In this context,
the term sex refers to identification as male or
female according to reproductive organs and func-
tions assigned by chromosomal complement. Sex
factors that contribute to the biological differences
include chromosomes, reproduction, and hor-
mones. Gender refers to socially defined and
derived expectations and roles rooted in biology
and shaped by environment and experience.
Gender and sex are important considerations in
most areas of research, including basic biological,
psychological, social, and behavioral studies.
Consideration of these variables is critical to the
accurate interpretation and validation of research
affecting women’s health. These variables determine
how health or disease processes may differ among
women or between men and women.
Health disparities/differences and diversity.
Women are disproportionately affected by some
conditions and diseases in terms of incidence,
diagnosis, course, and response to treatment.
Some populations of women may be at higher risk
for adverse disease outcomes because of factors
such as: biology, genes, culture, education, effects
of poverty, access to care, quality of care, and
access to opportunities for inclusion as research
subjects in clinical trials and studies. Thus, clini-
cal research should include, but not be limited to,
population-speciﬁc characteristics such as cultural
diversity, race/ethnicity, immigrant status, rural or
inner-city residency status, effects of poverty or
low socioeconomic status, sexual orientation, and
physical or mental disabilities.
Interdisciplinary research. With increasing
understanding of the interrelatedness and com-
plexity of disease, the nature of scientiﬁc investiga-
tion is shifting to an interdisciplinary collaborative
approach. Advances in women’s health can be bet-
ter achieved by promoting partnerships across dis-
ciplines. Interdisciplinary approaches can integrate
knowledge from multiple specialties and disci-
plines, thus enhancing the likelihood of defining
underlying pathologic processes. Collaborations
among researchers in academia, private industry,
and federal settings can provide access to the latest
scientific tools and technologies and expertise for
women’s health research.
Areas for Women’s Health Research. Basic,
clinical and translational research should be consid-
ered in addressing priority areas in women’s health
research. Some examples may include, but are not
limited to: 1) Diseases and conditions that affect
women. Investigate the pathogenesis and develop
preventive and therapeutic interventions for acute
and chronic diseases and disorders that affect
women including, but not limited to, metabolic,
inflammatory, endocrine, autoimmune, gastro-
intestinal, liver, urologic, ophthalmic, oral, repro-
ductive, musculoskeletal, neurological, psychiatric,
and cardiovascular diseases; 2) Methodological
advances. Develop clinical trial methodology,
including novel recruitment strategies, standard-
ized outcome strategies, and statistical analyses that
address ethical and study design issues specific to
studies of women. Develop new methodologies for
animal model studies of the normal development
of women, and their health and diseases, including
female animal models. Methodological studies
related to the conceptualization, distinction, and
detection of sex and gender differences in basic and
clinical biomedical research; 3) Education and
career development of women in science. Identify
and explore factors that affect the selection and
advancement of women’s careers in biomedical sci-
ences. Implement novel education programs
directed at girls and women. Promote unique pro-
grams for addressing impediments to the advance-
ment and effective mentoring of women to senior
positions in science; 4) Quality of life. Elucidate
the unique sex and gender factors affecting
women’s quality of life. Develop approaches to
management of disease and promotion of wellness
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that are directed at women and their unique issues;
5) Research collaborations and partnerships. Foster
special trans-NIH, trans-DHHS, and public–pri-
vate research partnerships and collaborations in
appropriate areas of research and career develop-
ment related to women’s health.
The NIH is interested especially in fostering
research in women’s health in the high-priority areas
of prevention and treatment, and the biological and
behavioral basis of sex and gender differences.
Prevention, treatment, and treatment
outcomes. Increased investigation into methods to
prevent conditions and diseases, or to optimize
treatment, can result in significant improvements
in the quality and length of women’s lives.
Prevention research spans the continuum from the
most basic biological studies to understanding the
bases and effects of risk behaviors across the lifes-
pan and the interventions to change them, includ-
ing a focus on wellness and healthy behaviors.
Examples of needed prevention and treatment
research studies in women’s health include, but are
not limited to: 1) Research to identify and validate
biomarkers, including genetic polymorphisms, of
disease risk, pathogenesis, progression, and their
applications to disease prevention, early detection
and treatment, including the development of
novel tools; 2) Studies of the impact on health of
diet, nutrition, hormones, exercise, weight pat-
terns, toxin exposures, obesity, sex practices, men-
tal health disorders, including eating disorders,
tobacco, alcohol and drug use or abuse, occupa-
tion, violence, or trauma. Studies of the factors
that are involved in disease initiation and progres-
sion, both biologic and behavioral, in order to
develop effective preventive and treatment strate-
gies; 3) Development, testing, and validation of
preventive, early detection, and treatment strate-
gies for conditions and diseases including, but not
limited to, sexually transmitted diseases, cancer,
coronary artery disease, stroke, obesity, diabetes,
musculoskeletal disorders, pain syndromes, addic-
tions, mental health, and chronic multisystemic
diseases; 4) Studies of the effect of biological,
behavioral, cultural, social, economic, and envi-
ronmental factors on susceptibility to, or protec-
tion from, disease and response to treatment, such
as individualized medicine and subset analyses,
when appropriate.
Biological and behavioral basis of sex and
gender differences. Whereas there has been much
research to identify the function of cellular path-
ways and genes, research on the effects of sex as a
modiﬁer of cellular and gene function is underin-
vestigated. Systemic and cellular modeling of the
inﬂuence of sex differences in biological pathways
and systems is needed, including, but not limited
to: 1) determination of sex differences that may
modify the role of known cellular pathways;
2) effect of sex differences on the expression and
function of genes, genetic polymorphisms, and
gene defects in the risk factors, etiology, severity,
and response to treatment of common diseases
and those that disproportionately affect women; 3)
sex and gender differences in prevention, patho-
genesis, course, response to treatment, and preven-
tion, using basic, translational, behavioral, and
clinical research approaches; 4) mechanism of sex
effects on gene expression and cellular and signal-
ing pathways in healthy women, including the
impact of puberty, the menstrual cycle, pregnancy,
and menopause; 5) genetic, molecular, and cellular
basis of action of pharmacologic agents in women,
including differential effects between males and
females; 6) development of novel methods of
analysis to assist in discerning impact of sex in
mechanisms of disease initiation, course, and
response to treatment or other interventions; 7)
effect of biologic and behavioral sex and gender
difference on quality of life and quality of care.
An Agenda for Research on Women’s Health
for the 21st Century. The ORWH has published
“An Agenda for Research on Women’s Health for
the 21st Century,” A report of the task force on the
NIH Women’s Health Research Agenda for the
21st Century, based on a series of four scientific
workshops. This outline represents the recommen-
dations from these national meetings examining
research needs for women’s health: 1) scientific
areas, 2) sex and gender perspectives throughout
the life cycle; and 3) differences among populations
of women throughout the life cycle. The executive
summary of these outcomes is available at the
following URL: http://orwh.od.nih.gov/research/
resagenda.html.
The Institute of Medicine Report, “Exploring
the Biological Contributions to Human Health,
Does Sex Matter?” This report, published in 2001,
includes three overarching conclusions: 1) Sex mat-
ters. Sex—that is, being female or male—is an
important basic human variable that should be con-
sidered when designing and analyzing studies in all
areas and at all levels of biomedical and health-
related research. 2) The study of sex differences is
evolving into a mature science. There is now sufﬁ-
cient knowledge of the biological basis of sex differ-
ences to validate the scientific study of sex
differences, and to allow the generation of hypothe-
ses. 3) Barriers to the advancement of knowledge
about sex differences in health and illness exist and
must be eliminated. The report states that the ques-
tion of sex needs to be routinely asked in research
studies, and the results, positive or negative, need to
be routinely reported in order to advance our
understanding of the pathogenesis of disease.
This report also discusses the terms “sex” and
“gender,” and how they are sometimes used inter-
changeably in research literature. The report deﬁnes
sex as “the classiﬁcation of living things, generally as
male or female according to their reproductive
organs and functions assigned by their chromoso-
mal complement, and gender as a person’s self-
representation as male or female, or how that
person is responded to by social institutions on the
basis of the individual’s gender presentation.
Gender is shaped by environment and experience.”
Thus, sex is a biological construct whereas gender is
a psychosocial construct. This distinction notwith-
standing, epigenetic research reveals that biological
factors often unfold in ways that are inﬂuenced by
the environment and thus can obviate this distinc-
tion between sex and gender.
Therefore, because it is often not known a
priori whether a female—male difference is sex-
based, gender-based or both, in this program
announcement “sex/gender difference” will be
used generically to refer to female—male differ-
ences regardless the origins of the differences,
although a search for those origins is a major focus
of this announcement.
In nonhuman animal research, however, the
term “sex difference” is the preferred term.
Additionally, researchers are encouraged to recog-
nize that a sex/gender difference is sometimes only
a proxy for an unidentified independent
variable(s). Thus, finding a sex/gender difference
typically should be regarded as a first step in a
search for such variables as their identiﬁcation will
shed light on the phenomenon under study. For




In addition to the three main resources pre-
sented above, other examples of areas of interest
are offered as a guide to interested investigators.
Sex and gender differences include: 1) sex/
gender differences in the basic behavioral, biologi-
cal, and genetic mechanisms underlying diseases
and conditions that predominantly affect women;
and laboratory, epidemiological, and clinical stud-
ies of sex/gender differences in the etiology, onset,
and progression in these disorders and conditions;
2) the genetic basis of sex/gender differences, using
a variety of methodologies, such as  statistics or
epidemiology to ascertain heritability; identifica-
tion of genetic variants through linkage, linkage
disequilibrium, or association studies; identifica-
tion of candidate genes using knockout or overex-
pression technologies in model organisms in
model organisms; gene expression studies; 3) sex
differences in hormonal, psychosocial, and cogni-
tive function; 4) female—male differences in how
the transition to puberty and adolescent physique
characteristics inﬂuence the onset and progression
of disorders and conditions that affect predomi-
nantly women; 5) sex/gender differences in the
perception of pain and in efﬁcacy of both pharma-
cological and nonpharmacological pain treat-
ments; 6) design, develop, and validate preventive,
early detection, and treatment strategies that use
sex/gender-based theories (e.g., psychosocial, bio-
logical, developmental) and empirical ﬁndings on
the risk and protective factors related to onset,
progression, and treatment of diseases and condi-
tions such as obesity, diabetes, musculoskeletal
disorders, chronic pain syndromes, addictions,
metabolic, inﬂammatory, endocrine, autoimmune,
gastrointestinal, urologic, ophthalmic, oral, repro-
ductive, neurological, psychiatric, and chronic
multisystemic diseases; 7) examine the impact of
key variables such as diet, nutrition, weight pat-
terns on treatment outcomes in females and males;
8) study the effect of biological, behavioral, cul-
tural, social, economic, and environmental factors
on susceptibility to, or protection from, disease
and response to treatment, such as individualized
medicine and subset analyses, when appropriate.
Cross-cutting issues include: 1) address and
compare stages of the life cycle, from intrauterine,
to infancy, childhood, adolescence, adulthood, late
adulthood, and elderly; 2) examine the role of
race, ethnicity, culture, and socioeconomic class in
conditions and disorders that affect women;
3) examine health disparity issues in chronic and
infectious diseases and disorders that affect women;
4) study issues of females in underserved popula-
tions, e.g., rural or inner-city residence, homeless,
victims of violence, migrant workers; 5) use and
develop methodological approaches, including
longitudinal studies, secondary data analyses,
descriptive studies, novel measurement tools, and
interdisciplinary approaches; 6) examine sex/gender-
speciﬁc recruitment and retention issues; 7) identify
triggers of inﬂammatory processes, roles of hormone
receptor activation in inﬂammatory responses, andinteractions of sex hormones with pathogen responses
in altering inﬂammatory and immune responses after
injury. In FY 2006, ORWH held a scientiﬁc work-
shop entitled, “Regulation of Inflammatory
Responses: Inﬂuence of Sex and Gender.” A detailed
summary from this workshop can be found at http://
orwh.od.nih.gov/Inﬂammation_Summary.html.
Institute/Center-Speciﬁc Research Interests and
Requests. In addition to the research guidelines
stated above, the following NIH institutes and cen-
ters state the following: 1) NIAID is interested in
projects involving HIV and opportunistic infections;
2) NIDCR has a policy that R21 applications can-
not be used for small clinical trials; 3) NIGMS is
interested in research into sex differences related to
the clinical areas that it supports in pharmacology,
anesthesiology, and the physiological sciences related
to traumatic injury and burn, and wound healing;
4) NINDS will support new research projects that
assess the feasibility of a novel avenue of investiga-
tion, involve high-risk experiments that could lead
to a breakthrough in a particular field, or demon-
strate the feasibility of new technologies that could
have major impact in a speciﬁc area. Proposals sub-
mitted under this mechanism should be limited to
those with the potential for truly ground-breaking
impact. NINDS will also support projects in transla-
tional research intended to discover potential targets
for therapeutic intervention, to identify candidate
therapeutics, or to develop assays, animal models,
devices, or technologies for screening or developing
therapeutics. NINDS, however, will not support
R21 applications that include clinical trials or other
clinical studies of potential therapies. For further
details regarding NINDS use of the R21 mechanism
see the NINDS website: http://www.ninds.nih.gov/
funding/r21guidelines.htm. Applicants are encour-
aged to contact appropriate program staff within
NINDS for advice about potential R21 proposals;
5) NLM is interested in topics related to biomedical
informatics and knowledge management; 6) OBSSR
is interested in promoting research on the behavioral
and social aspects of health and illness.
Under this PAS, investigators may request funds
to perform secondary data analyses of either their own
data sets or other data sets that are publicly available.
This FOA will use the NIH Exploratory/
Developmental Research Grant (R21) award mecha-
nism. As an applicant, you will be solely responsible
for planning, directing, and executing the proposed
project.
This FOA uses “Just-in-Time” information con-
cepts. It also uses the modular as well as the non-
modular budget formats (see the “Modular
Applications and Awards” section of the NIH Grants
Policy Statement. Speciﬁcally, if you are submitting
an application with direct costs in each year of
$250,000 or less (excluding consortium Facilities and
Administrative [F&A] costs), use the PHS398
Modular Budget component provided in the SF424
(R&R) Application Package and SF424 (R&R)
Application Guide (see specifically Section 5.4,
“Modular Budget Component,” of the Application
Guide).
All foreign applicants must complete and sub-
mit budget requests using the Research & Related
Budget component found in the application pack-
age for this FOA. See NOT-OD-06-096, 23
August 2006.
Exploratory/developmental grant support is for
new projects only; competing renewal (formerly
“competing continuation”) applications will not be
accepted. Up to two resubmissions (formerly
”revisions/amendments”) of a previously reviewed
exploratory/developmental grant application may
be submitted. See NOT-OD-03-041, 7 May 2003.
Applicants must download the SF424 (R&R)
application forms and SF424 (R&R) Application
Guide for this FOA through Grants.gov/Apply.
Note: Only the forms package directly attached
to a speciﬁc FOA can be used. You will not be able
to use any other SF424 (R&R) forms (e.g., sample
forms, forms from another FOA), although some of
the “Attachment” files may be useable for more
than one FOA.
For further assistance, contact GrantsInfo:
301-435-0714, (telecommunications for the hear-
ing impaired: TTY 301-451-0088) or by e-mail:
GrantsInfo@nih.gov.
The application submission dates for this PAS
are available at http://grants.nih.gov/grants/fund-
ing/submissionschedule.htm. The complete version
of this PAS is available at http://grants.nih.gov/
grants/guide/pa-ﬁles/PAS-07-381.html.
Contacts: The complete list of agency contacts
is available at http://grants.nih.gov/grants/guide/
pa-ﬁles/PAS-07-381.htm. Reference: PAS-07-381.
NIAID International Research in Infectious
Diseases (IRID) Program (R01) 
The National Institute of Allergy and Infectious
Diseases (NIAID) encourages the submission of
R01 applications from institutions in eligible for-
eign countries to conduct studies and establish col-
laborative infectious diseases research among
investigators and institutions at international sites
where NIAID has signiﬁcant investment in research
and/or infrastructure (see below for list of NIAID
programs). These grants will serve to build indepen-
dent research capacity by providing direct funding
to investigators who do not currently have NIAID-
funded grant awards for research projects. The
intent of these activities is to advance the develop-
ment of local scientific expertise, build local
research infrastructure, and increase collaborative
research partnerships at NIAID international sites.
Collaborative projects involving investigators
and institutions from international sites and the
United States are particularly encouraged; a U.S.
partner is not required. NIAID has a long-standing
interest in and commitment to global health and
international research. Topics of interest for this
program are limited to research on infectious dis-
eases, including emerging infections that are of the
greatest public health signiﬁcance within the appli-
cant country (e.g., tuberculosis, malaria, HIV/AIDS,
sexually transmitted diseases, diarrheal, respiratory,
and enteric diseases, viral hemorrhagic fevers, viral
encephalitides, parasitic diseases, and vector-borne
diseases). Development of immunological, microbi-
ological, biostatistical, epidemiological, and clinical
research capacity is encouraged. Studies may be pro-
posed on any aspect of infectious diseases (except
clinical trials), including but not limited to the epi-
demiology, pathogenesis, immunopathogenesis of
infectious diseases; epidemiologic studies to define
the incidence, clinical presentations, and outcomes
of diseases, identiﬁcation of resistance patterns, char-
acterization of susceptible cohorts for a particular
pathogen; pilot and feasibility studies in preparation
for larger studies.
NIAID supports a number of international
research programs on infectious diseases, including
HIV/AIDS. These include the International
Centers of Excellence in Research (ICERs),
International Collaborations for Infectious Disease
Research (ICIDRs), the Tropical Medicine
Research Centers (TMRCs), the Tuberculosis
Research Program, the HIV Vaccine Trials
Network (HVTN), and the HIV Prevention Trials
Network (HPTN).
This International Research in Infectious
Diseases (IRID) Program (R01) is intended to
extend these programs by expanding the breadth of
research supported at international sites and by pro-
viding support to new researchers. Applications
from institutions in eligible countries where NIAID
has significant investments through extramural
research grants, cooperative agreements or contracts
or through programs of the NIAID Division of
Intramural Research are particularly encouraged.
However, current NIH or NIAID funding is not
a requirement.
Clinical trials will not be supported. When
noninterventional clinical studies are a component
of the research proposed, NIAID policy requires
that studies be monitored commensurate with the
degree of potential risk to study subjects and the
complexity of the study. AN UPDATED NIAID
policy was published in the NIH Guide on 8 July
2002 and is available at: http://grants.nih.gov/
grants/guide/notice-files/NOT-AI-02-032.html.
The full policy, including terms and conditions of
award, is available at http://www.niaid.nih.gov/
ncn/pdf/clinterm.pdf).
This Funding Opportunity Announcement
(FOA) will use the NIH Research Project Grant
(R01) award mechanism.  
The applicant will be solely responsible for
planning, directing, and executing the proposed
project. 
This FOA uses “Just-in-Time” information
concepts. It also uses the nonmodular budget for-
mats (see http://grants.nih.gov/grants/funding/
modular/modular.htm). All foreign applicants must
complete and submit nonmodular budget requests
using the Research & Related Budget component
found in the application package for this FOA. See
NOT-OD-06-096, 23 August 2006.    
At this time, it is not known if competing
renewal (formerly “competing continuation”) appli-
cations will be accepted and/or if this FOA will be
reissued.
Applicants must download the SF424 (R&R)
application forms and the SF424 (R&R) Application
Guide for this FOA through Grants.gov/Apply.
Note: Only the forms package directly attached
to a speciﬁc FOA can be used. You will not be able
to use any other SF424 (R&R) forms (e.g., sample
forms, forms from another FOA), although some of
the “Attachment” files may be useable for more
than one FOA.
For further assistance, contact GrantsInfo:
301-435-0714 (telecommunications for the hearing
impaired: TTY 301-451-0088) or by e-mail:
GrantsInfo@nih.gov.
The application receipt dates for this PAR are
26 September 2007 and 2008. The complete ver-
sion of this PAR is available at http://grants.nih.
gov/grants/guide/pa-ﬁles/PAR-07-376.html.
Contacts: The complete list of agency contacts
is available at http://grants.nih.gov/grants/guide/
pa-ﬁles/PAR-07-376.html. Reference: PAR-07-376.
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